Kivu Bioscience president and COO Mohit Trikha (L) and Novo Holdings partner, venture investments Daniel O’Connell
October 28, 2024 08:00 AM EDTUpdated 09:47 AM
Financing
Startups

Synaf­fix, in­dus­try's ADC part­ner of choice, spins out a start­up pipeline

Kyle LaHucik

Senior Reporter

The Dutch biotech Synaf­fix has long been one of the top part­ners for bio­phar­ma com­pa­nies work­ing in an­ti­body-drug con­ju­gates. Now the com­pa­ny is spin­ning out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times